Different molecular patterns in glioblastoma multiforme subtypes upon recurrence

被引:0
作者
Ramon Martinez
Veit Rohde
Gabriele Schackert
机构
[1] University of Göttingen,Department of Neurosurgery
[2] University of Dresden,Department of Neurosurgery
来源
Journal of Neuro-Oncology | 2010年 / 96卷
关键词
Glioblastoma; Relapse; Microsatellite; Mutation;
D O I
暂无
中图分类号
学科分类号
摘要
One of the hallmarks of glioblastoma is its inherent tendency to recur. At this point patients with relapsed GBM show a survival time of only few months. The molecular basis of the recurrence process in GBM is still poorly understood. The aim of the present study was to investigate the genetic profile of relapsed GBM compared to their respective primary tumors. We have included 20 paired GBMs. In all tumor samples, we have analyzed p53 and PTEN status by sequencing analysis, EGFR amplification by semiquantitative PCR and a wide-genome fingerprinting was performed by microsatellite analysis. Among primary GBM, we observed twelve type 2 GBM, four type 1 GBM and four further GBM showing neither p53 mutations nor EGFR amplification (non-type 1–non-type 2 GBM). Upon recurrence, we have detected two molecular patterns of tumor progression: GBM initially showing either type 1 or type 2 profiles conserved them at the time of relapse. In contrast, non-type 1–non-type 2 GBM acquired the typical pattern of type 2 GBM and harbor EGFR amplification without p53 mutation. New PTEN mutations upon relapse were only detected in type 2 GBM. Additional LOH were more frequently identified in relapses of type 2 GBM than in those showing the type 1 signature. Taken together, our results strongly suggest that recurrences of GBM may display two distinct pattern of accumulation of molecular alterations depending on the profile of the original tumor.
引用
收藏
页码:321 / 329
页数:8
相关论文
共 290 条
[1]  
Brandes AA(2001)Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study Ann Oncol 12 255-257
[2]  
Ermani M(2002)Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 1375-1382
[3]  
Basso U(1980)Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1323-1329
[4]  
Amistà P(2008)Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Lancet Oncol 9 29-38
[5]  
Berti F(1996)Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas Oncogene 13 661-664
[6]  
Scienza R(1999)Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences Oncogene 18 1385-1390
[7]  
Rotilio A(2004)Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours J Neurol Neurosurg Psychiatry 75 723-726
[8]  
Pinna G(1994)Frequency of allele loss of DCC, p53, RB1, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction Br J Cancer 70 813-818
[9]  
Gardiman M(1995)Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue J Neuropathol Exp Neurol 54 57-64
[10]  
Monfardini S(1997)Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome Nat Genet 16 64-67